# Clinical Trials Data KRAS - Document 39

# COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01596790

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Age \\> 18 years\n\* Colon or rectum adenocarcinoma (based on the histology)\n\* Visceral metastases (synchronous and/or metachronous)\n\* Metastatic disease measurable with the RECIST 1.1 criteria\n\* WHO performance status 0, 1 or 2\n\* Life expectancy\\>3 months when starting the treatment\n\* Chemotherapy in metastatic 1rst line combining a protocol of conventional chemotherapy combining 5-FU and IRINOTECAN (FOLFIRI, XELIRI) associated with bevacizumab\n\* Follow-up of at least one year\n\* Collection of the written consent\n\* Social security affiliation\n\nExclusion Criteria:\n\n\* 2nd line chemotherapy and beyond\n\* History of other cancers considered not cured\n\* Active and progressive infection or other serious disease that may not allow the patient to receive the treatment\n\* refusal to participate\n\* Patient unable to express his consent\n\* Pregnant women\n\* Patient unable to be followed-up for at least one year\n\* Current participation to another clinical trial\n\* Patients under guardianship\n\* Vulnerable people protected by the law",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, there is no mention of the KRAS gene mutation as part of the inclusion or exclusion criteria. Therefore, a patient with a KRAS gene mutation could be eligible for this clinical trial, as the criteria do not explicitly exclude such patients. However, it would be essential for the patient to meet all the inclusion criteria and not meet any of the exclusion criteria to be eligible. It is always advisable for patients or healthcare providers to confirm with the trial administrators for specific genetic considerations or additional criteria not listed in the general information.